Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients

M. Boaz*, Z. Matas, A. Biro, Z. Katzir, M. Green, M. Fainaru, S. Smetana

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Hemodialysis (HD) patients have accelerated cardiovascular morbidity and mortality rates compared with the general population. Identifying the factors that predict major coronary events in this population can direct the focus on prevention. This cross-sectional study compares known and suspected cardiovascular risk factors in HD patients with and without prevalent cardiovascular disease (CVD). In 76 HD patients (prevalent CVD, 44 of 76 patients), serum lipid, lipoprotein, apolipoprotein (Apo), plasma fibrinogen, tissue plasminogen activator (TPA), plasminogen activator inhibitor (PAI-1), and factor VII levels were measured using standard kits. Serum malondialdehyde (MDA; a marker of oxidative stress) was measured using spectrophotometry. Predictor variables were compared using analysis of variance and chi-squared tests, as appropriate. CVD prevalence was modeled using multiple logistic regression analysis, and odds ratios (OR) were calculated. Serum lipid, lipoprotein, Apo, plasma TPA, PAI-1, and factor VII values did not differ significantly from laboratory norms or discriminate for prevalent CVD in HD patients. Plasma fibrinogen levels were significantly elevated in HD patients compared with laboratory norms (369.4 ± 130.02 v 276.7 ± 77.7 mg/dL; P < 0.0001) but were not significantly different in HD patients with and without prevalent CVD. Serum MDA levels, both before and after the midweek HD treatment, were significantly elevated in all HD patients compared with laboratory norms (pretreatment, 2.6 ± 0.8 nmol/mL; posttreatment, 2.1 ± 0.3 v 0.91 ± 0.09 nmol/mL; P < 0.01) and were significantly elevated in HD patients with prevalent CVD versus those without (pretreatment, 2.8 ± 0.6 v 2.4 ± 0.4 nmol/mL; P < 0.01; posttreatment, 2.3 ± 0.4 v 1.94 ± 0.2 nmol/mL; P < 0.01). Only serum MDA levels, both before and after the midweek treatment, contributed to the explanation of variation in CVD prevalence. OR for CVD in the highest versus lowest tertile of pretreatment MDA level was 2.71 (95% confidence interval [CI], 1.42 to 5.1,9). ORs for CVD in the highest versus lowest tertile of posttreatment MDA level was 3.65 (95% CI, 1.6 to 8.32).

Original languageEnglish
Pages (from-to)438-444
Number of pages7
JournalAmerican Journal of Kidney Diseases
Volume34
Issue number3
DOIs
StatePublished - 1999
Externally publishedYes

Keywords

  • Cardiovascular disease
  • Hemostatic factors
  • Malondialdehyde
  • Oxidative stress

Fingerprint

Dive into the research topics of 'Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients'. Together they form a unique fingerprint.

Cite this